Posted by iforgotmypassword on May 8, 2009, at 1:54:58
In reply to Anyone in clinical trials for Lu AA21004 ?, posted by NegCreep on May 6, 2009, at 11:11:14
i prefer the sound of this drug over that other 5-HT1a agonist in the pipeline, vilazodone i think it is called, which seems to lack the effects of a real 5-HT1a agonist in vivo. it's actual relevant action may be it's supposed "secondary" SRI effect. just what we need, another SSRI to waste time promoting.
this drug, Lu AA21004, appears to be a real 5-HT1a agonist, that is to say it releases catecholamines in the PFC as associated with the actions of an 5-HT1a agonist. curiously however, it also increases extracellular serotonin, an effect very unlike what is expected with 5-HT1a agonism, which is supposed to decrease extracellular serotonin concentrations. this may be an effect of the 5-HT3 antagonism, i would like to know more about that, and where exactly the extracellular serotonin concentrations would be increased and what the neuropsychiatic complications may be understood or theorised as being.
poster:iforgotmypassword
thread:894465
URL: http://www.dr-bob.org/babble/20090505/msgs/894738.html